Numinus is valid for filing international patents for the psychedelic production process

The deposit will offer additional protection to IPs already submitted to the USPTO

Vancouver, BC, June 22, 2022 / PRNewswire / – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company that promotes innovative and safe treatments based on evidence-based psychedelic therapies, announced today that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has applied for a patent to the World Intellectual Property Organization (WIPO), a United Nations organization, for a rapid production process for Psilocybe and other fungal species containing psilocybin and other compounds.

An interim patent application for the procedure was filed with the United States Patent and Trademark Office (USPTO) on June 24, 2021. With this additional filing, international patent protection will be extended to all WIPO Member States that have signed the Patent Cooperation Treaty (PCT), including Australia, Germany, Netherlands and United Kingdomwhere psychedelic research is currently active.

“WIPO is an important global forum that provides assurances to Member States’ patent offices. Numinus is confident that strong data supporting the production process will further inform regulators as they consider policy changes to make treatments more accessible and psychedelic-assisted products, “he said Sharan Sidhu, Vice President, Scientific Research, Innovation & Laboratory Operations, Numinus. “We look forward to advancing current research and paving the way for final commercialization and mainstream access.”

The purpose of the procedure is to significantly increase the production of therapeutic drugs for use in psychedelic assisted therapy, while reducing product variability, increasing production efficiency and ultimately reducing commercialization costs. From the initial filing, the data sets validating the process for additional fungi have been completed, extending the possible application and range of psilocybin to other active compounds.

“This application is part of Numinus PO’s long-term focus strategy on scalable and sustainable production that promotes research, development and delivery of innovative psychedelic preparations. North America and beyond, “he said Payton NyquvestFounder and CEO, Numinus.

About Numinus

Numinus Wellness helps people heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic therapies. The Numinus model – including psychedelic production, research and clinical care – is at the forefront of a transformation aimed at treating rather than managing the symptoms of depression, anxiety, trauma, pain and substance use. At Numinus, we lead the integration of psychedelic-assisted therapies into core clinical practice and build the foundation for a healthier society.

Learn more at numinus.com and follow us on LinkedIn, Facebook, Twitterand Instagram.

Denial of responsibility

Neither Numinus Wellness Inc. nor any of its subsidiaries are professional licensed health care providers. In jurisdictions where health services can only be provided by a company if that company has a valid license to do so, Numinus and its subsidiaries act as management services to affiliated professional companies providing health services to patients. Numinus and its subsidiaries provide health services directly to patients in those jurisdictions where they are authorized to do so.

Future statements

The statements and other information contained in this press release regarding expected future events are forward-looking statements. Future statements are often, but not always, defined using words such as “seek”, “anticipate”, “believe”, “plan”, “appreciate”, “expect” and “intend” and statements that “can” occur. “would”, “should”, “could” or “can” occur or other similar expressions. Future statements are subject to risks and uncertainties and other factors that could cause the actual results to differ significantly from those contained in the future statements. Future statements are based on management’s estimates and views at the date the statements are made. The Company undertakes no obligation to update future statements, even if the circumstances or the estimates or views of management change, unless required by applicable law. Investors should not unduly rely on future statements.

Cision

See the original content: https: //www.prnewswire.com/news-releases/numinus-applies-for-international-patent-filing-of-psychedelics-production-process-301572540.html

SOURCE Numinus Wellness Inc.

Leave a Reply

Your email address will not be published.